Oncology The future of oncology is adaptive: What ESMO 2026 revealed ... Across tumours, three developments repeatedly surfaced throughout the congress, each reflecting a notable transition in how cancer is being managed.
Oncology On the benefits of earlier oncological intervention, with Jo... As ESMO 2026 came to a close, pharmaphorum web editor Nicole Raleigh spoke with Johnson & Johnson Innovative Medicine’s Carolyn Sousa and Henar Hevia
Oncology In vivo CAR-T can solve the delivery problem – but solid tum... A new generation of in vivo CAR-T cell technologies promises to remove some of the biggest practical barriers to conventional cell therapy.
Oncology Australia, CAR-T therapy, and solid tumours Bev Menner, chief executive officer at Cell Therapies Pty Ltd, discusses CAR-T therapies for solid tumours and Australian and APAC R&D more generally.
Oncology How today’s biotechs are helping us Stand Up To Cancer In recognition of Stand Up To Cancer Day, a look at next-generation treatments that are on the verge of making it into clinical practice.
Oncology Bridging the innovation gap: Scalable cell therapies, adapti... Biotech must build manufacturing and trial models that make cell therapies scalable, accessible & commercially viable.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.